Acute Hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction:: The ECLIPSE international, multicenter, randomized, placebo-controlled trial

被引：6

作者：

Udelson, James E. ^{[1
]}

Orlandi, Cesare ^{[2
]}

Ouyang, John ^{[2
]}

Krasa, Holly ^{[2
]}

Zimmer, Christopher A. ^{[2
]}

Frivold, Geir ^{[3
]}

Haught, W. Herbert ^{[4
]}

Meymandi, Sheba ^{[5
]}

Wedge, Patricia ^{[6
]}

Konstam, Marvin M. ^{[1
]}

Gheorghiade, Mihai ^{[7
]}

机构：

[1] Tufts Univ New England Med Ctr, Boston, MA USA

[2] Otsuka Amer Pharmaceut Inc, Rockville, MD USA

[3] VA Loma Linda Healthcare Syst, Loma Linda, CA USA

[4] Ctr Head, Huntsville, AL USA

[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[6] Cardiovasc Clin Trials, Boston, MA USA

[7] Northwestern Univ, Sch Med, Chicago, IL 60611 USA

来源：

JOURNAL OF CARDIAC FAILURE | 2007年 / 13卷 / 09期

关键词：

D O I：

10.1016/j.cardfail.2007.10.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：793 / 794

页数：2

共 50 条

[1] Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International, Multicenter, Randomized, Placebo-Controlled Trial
Udelson, James E.
Orlandi, Cesare
Ouyang, John
Krasa, Holly
Zimmer, Christopher A.
Frivold, Geir
Haught, W. Herbert
Meymandi, Sheiba
Macarie, Cezar
Raef, Dimitar
Wedge, Patricia
Konstam, Marvin A.
Gheorghiade, Mihai
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (19) : 1540 - 1545
[2] Vasopressin V2 Receptor Antagonist Tolvaptan is Effective in Heart Failure Patients With Reduced Cardiac Systolic Function
Suzuki, Satoshi
Yoshihisa, Akiomi
Yamaki, Takayoshi
Sugimoto, Koichi
Kunii, Hiroyuki
Nakazato, Kazuhiko
Abe, Yukihiko
Saito, Tomiyoshi
Ohwada, Takayuki
Saitoh, Shu-ichi
Kubota, Isao
Takeishi, Yasuchika
CIRCULATION, 2013, 128 (22)
[3] A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Tolvaptan Monotherapy Compared to Furosemide and the Combination of Tolvaptan and Furosemide in Patients With Heart Failure and Systolic Dysfunction
Udelson, James E.
Bilsker, Martin
Hauptman, Paul J.
Sequeira, Rafael
Thomas, Ignatius
O'Brien, Terrence
Zimmer, Christopher
Orlandi, Cesare
Konstam, Marvin A.
JOURNAL OF CARDIAC FAILURE, 2011, 17 (12) : 973 - 981
[4] Acute Effect of the V2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized with Heart Failure: Results of the SECRET of CHF
Konstam, Marvin A.
Kiernan, Michael
Chandler, Arthur
Dhingra, Ravi
Mody, Freny
Eisen, Howard
Haught, W. Herbert
Wagoner, Lynne
Gupta, Divya
Patten, Richard
Gordon, Paul
Korr, Kenneth
Fileccia, Russell
Gregory, Douglas
Wedge, Patricia
Romeling, Matthew
Konstam, Jeremy M.
Udelson, James E.
JOURNAL OF CARDIAC FAILURE, 2016, 22 (11) : 939 - 939
[5] Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
Udelson, James E.
McGrew, Frank A.
Flores, Enrique
Ibrahim, Hassan
Katz, Stewart
Koshkarian, Gregory
O'Brien, Terrence
Kronenberg, Marvin W.
Zimmer, Christopher
Orlandi, Cesare
Konstam, Marvin A.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (22) : 2151 - 2159
[6] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
Udelson, JE
Smith, WB
Hendrix, GH
Painchaud, CA
Ghazzi, M
Thomas, I
Ghali, JK
Selaru, P
Chanoine, F
Pressler, ML
Konstam, MA
CIRCULATION, 2001, 104 (20) : 2417 - 2423
[7] Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial
Gheorghiade, M
Gattis, WA
O'Connor, CM
Adams, KF
Elkayam, U
Barbagelata, A
Ghali, JK
Benza, RL
McGrew, FA
Klapholz, M
Ouyang, J
Orlandi, C
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16): : 1963 - 1971
[8] The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure
Mentz, Robert J.
Felker, G. Michael
Cole, Robert
Adams, Kirkwood F.
Egnaczyk, Gregory
Fiuzat, Mona
Patel, Chetan B.
Echols, Melvin
Khouri, Michel
Tauras, James M.
Gupta, Divya
Monds, Pamela
Roberts, Rhonda
O'Connor, Christopher M.
JOURNAL OF CARDIAC FAILURE, 2016, 22 (11) : 939 - 939
[9] Vasopressin V2 Receptor Antagonist Tolvaptan Is Effective in Heart Failure Patients With Reduced Left Ventricular Systolic Function and Low Blood Pressure
Suzuki, Satoshi
Yoshihisa, Akiomi
Yamaki, Takayoshi
Sugimoto, Koichi
Kunii, Hiroyuki
Nakazato, Kazuhiko
Abe, Yukihiko
Saito, Tomiyoshi
Ohwada, Takayuki
Suzuki, Hitoshi
Saitoh, Shu-ichi
Kubota, Isao
Takeishi, Yasuchika
INTERNATIONAL HEART JOURNAL, 2015, 56 (02) : 213 - 218
[10] Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure
Suzuki, S.
Yoshihisa, A.
Abe, Y.
Saito, T.
Ohwada, T.
Suzuki, H.
Saitoh, S.
Kubota, I.
Takeishi, Y.
EUROPEAN HEART JOURNAL, 2014, 35 : 160 - 161

← 1 2 3 4 5 →